| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 07/31/2002 | EP1225894A1 Fab i inhibitors |
| 07/31/2002 | EP1225890A1 Rivastigmine for the treatment of ocular disorders |
| 07/31/2002 | EP0527801B1 Thiophene sulfonamides useful as carbonic anhydrase inhibitors |
| 07/31/2002 | CN1361768A Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| 07/31/2002 | CN1361760A Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators |
| 07/31/2002 | CN1361690A Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 07/31/2002 | CN1361689A Stable xylometazoline and oxymetazoline solution |
| 07/31/2002 | CN1360931A Nanometer luminous Dendrobium nobil medicine and its prepn |
| 07/31/2002 | CN1360921A Nanometer eyesight improving adhesive rehmannia medicine and its prepn |
| 07/31/2002 | CN1360916A Nanometer zhangyanming medicine for treating eye disease and its prepn |
| 07/31/2002 | CN1360915A Nanometer zuoci medicine for treating deafness and its prepn |
| 07/31/2002 | CN1088460C Process for isolating galanthamine |
| 07/31/2002 | CN1088366C Application of Erigeron breviscapus in treatment of glaucoma vision function decreasing |
| 07/31/2002 | CA2369462A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of pde4 isozymes |
| 07/30/2002 | US6426358 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| 07/30/2002 | US6426353 α v integrin receptor antagonists |
| 07/30/2002 | US6426344 Aryl and heteroaryl substituted indolealkanoic acids |
| 07/30/2002 | US6426341 Treatment for diabetic complications |
| 07/30/2002 | US6426066 Use of physiologically balanced, ionized, acidic solution in wound healing |
| 07/30/2002 | CA2236021C Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities: process of making metho ds of using and compositions thereof |
| 07/30/2002 | CA2110806C 4-(1h-pyrrol-1-yl)imidazoles with angiotensin ii antagonist activity |
| 07/25/2002 | WO2002057453A2 Polypetides and nucleic acids encoding same |
| 07/25/2002 | WO2002057452A2 Human proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | WO2002057413A2 Peptides for activation and inhibition of delta pkc |
| 07/25/2002 | WO2002057267A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | WO2002057242A2 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | WO2002057237A1 Hetero-tricyclic compounds having substituted amino groups |
| 07/25/2002 | WO2002057222A2 Thiol-based naaladase inhibitors |
| 07/25/2002 | WO2002057211A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | WO2002056911A1 Transplantation rejection inhibitors |
| 07/25/2002 | WO2002056890A1 Novel method and compositions for local treatment of meniere's disease, tinnitus and/or hearing loss |
| 07/25/2002 | WO2002056886A1 Angiogenesis inhibitors contaiing urea derivative as the active ingredient |
| 07/25/2002 | WO2002056877A1 Treatment of sleep disturbances |
| 07/25/2002 | WO2002056871A2 Histamine receptor antagonists |
| 07/25/2002 | WO2002056863A2 Sustained release drug delivery devices |
| 07/25/2002 | WO2002056827A2 Substituted felbamate derived compounds |
| 07/25/2002 | WO2002056804A2 Presbyopia treatment by lens alteration |
| 07/25/2002 | WO2002038077A3 L-histidine in ophthalmic solutions |
| 07/25/2002 | WO2002032901A3 Bridged piperazine derivatives |
| 07/25/2002 | WO2002032422A3 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/25/2002 | WO2002018379A3 7-oxo pyridopyrimidines |
| 07/25/2002 | WO2002015886A3 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 07/25/2002 | WO2002012461A3 Regulation of human membrane-type serine protease |
| 07/25/2002 | WO2001094413A3 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 07/25/2002 | WO2001092273A3 Benzenedicarboxylic acid derivatives |
| 07/25/2002 | WO2001090091A8 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 07/25/2002 | WO2001070222A3 Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| 07/25/2002 | WO2001068079A3 Viscoelastics for use in middle ear surgery |
| 07/25/2002 | WO2001002567A9 16405 receptor, a g-protein coupled receptor |
| 07/25/2002 | US20020099357 Ocular iontophoretic device and method for using the same |
| 07/25/2002 | US20020099209 Dihydrostilbene alkanoic acid derivatives |
| 07/25/2002 | US20020099207 Has activity as an antagonist to neurokinin 1 receptors; for therapy of benign prostatic hyperplasia (BPH) |
| 07/25/2002 | US20020099010 Neurogenic compositions and methods |
| 07/25/2002 | US20020099008 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor |
| 07/25/2002 | US20020098527 Gene recombinant antibody and antibody fragment thereof |
| 07/25/2002 | US20020098224 Comprising histamine, its receptor analog, serotonin and its receptor analog in an opthalmic solution or gel for reducing irritation due to infection, allergies, pollutants and other irritants in a pharmaceutically acceptable carrier |
| 07/25/2002 | DE10102944A1 Production of 3-cyano-1H-indol-7-yl)-(4-(4-fluorophenethyl)piperazin-1-yl)-methanone useful as a selective 5-HT2A antagonist comprises use of an indolecarboxylic acid ester as the starting material |
| 07/25/2002 | CA2435374A1 Presbyopia treatment by reducing and preventing lenticular disulfide crosslinks |
| 07/25/2002 | CA2435121A1 Histamine receptor antagonists |
| 07/25/2002 | CA2434939A1 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | CA2434636A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | CA2434156A1 Sustained release drug delivery devices |
| 07/25/2002 | CA2433313A1 Polypetides and nucleic acids encoding same |
| 07/25/2002 | CA2430634A1 Proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | CA2430577A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | CA2427058A1 Substituted felbamate derived compounds |
| 07/24/2002 | EP1225183A2 Human G-protein coupled receptor |
| 07/24/2002 | EP1225168A2 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| 07/24/2002 | EP1224945A1 Tension-relieving agents for ciliary muscle |
| 07/24/2002 | EP1224939A1 Interferon complex and medicinal use thereof |
| 07/24/2002 | EP1224935A2 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| 07/24/2002 | EP1224934A2 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| 07/24/2002 | EP1224932A1 Drugs inhibiting cell death |
| 07/24/2002 | EP1224285A2 27 human secreted proteins |
| 07/24/2002 | EP1224283A2 Human and rat fgf-20 genes and gene expression products |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224200A1 Tissue plasminogen activator-like protease |
| 07/24/2002 | EP1224195A1 C-aryl glucoside sglt2 inhibitors |
| 07/24/2002 | EP1224180A2 Substituted azoles |
| 07/24/2002 | EP1224175A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 07/24/2002 | EP1224174A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 07/24/2002 | EP1224173A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 07/24/2002 | EP1224171A1 Beta disubstituted metalloprotease inhibitors |
| 07/24/2002 | EP1224170A1 6-position substituted indoline, production and use thereof as a medicament |
| 07/24/2002 | EP1224155A2 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 07/24/2002 | EP1223981A1 Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| 07/24/2002 | EP1223974A2 Medicament in order to induce tolerance |
| 07/24/2002 | EP1223970A1 Short segments of dap-kinase |
| 07/24/2002 | EP1223966A2 Use of gdnf for treating corneal defects |
| 07/24/2002 | EP1223965A2 Modulation of angiogenesis |
| 07/24/2002 | EP1223950A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 07/24/2002 | EP1223929A1 Cannabimimetic indole derivatives |
| 07/24/2002 | EP1223925A2 Use of a fatty acid derivative for the treatment of external secretion disorders |
| 07/24/2002 | EP1223924A2 Use of csaids in rhinovirus infection |
| 07/24/2002 | EP0900218B1 Heterocyclic compounds |
| 07/24/2002 | EP0835263B9 Somatostatin peptides |
| 07/24/2002 | EP0799044B1 Topical ophthalmic formulations containing olopatadine for treating allergic eye diseases |
| 07/24/2002 | EP0687184B1 Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases |
| 07/24/2002 | CN1360507A Conjugates and method for production thereof, and their use for transporting molecules via biological membranes |
| 07/24/2002 | CN1360497A Controlled-release biocompatible ocular drug delivery implant devices and methods |